• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Summit Therapeutics (SMMT) Is Up 8.5% After Ivonescimab’s Phase III Biliary Cancer Survival Win

    Simply Wall St·08/27/2026 21:20:24
    Listen to the news
    • Earlier this week, Summit Therapeutics reported that partner Akeso’s Phase III HARMONi-GI1 trial in China showed ivonescimab plus chemotherapy improved overall survival, progression-free survival, and objective response rate versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer.
    • This new gastrointestinal cancer success adds to the previously published HARMONi non-small cell lung cancer data and ongoing U.S. FDA review of ivonescimab, underscoring how widely the drug’s bispecific design is being tested across tumor types.
    • Next, we’ll examine how ivonescimab’s Phase III overall survival win in biliary tract cancer affects Summit’s existing investment narrative.

    The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Summit Therapeutics Investment Narrative Recap

    To own Summit Therapeutics, you have to believe ivonescimab can convert its broad late stage data set into approvals and real-world use across several cancers. The new Phase III biliary tract cancer win in China showcases the drug’s versatility, but it does not change that the key near term catalyst is still the U.S. FDA’s HARMONi decision, or that the biggest risk remains a lack of overall survival benefit where regulators have clearly asked for it.

    Against this backdrop, the most relevant prior milestone is the FDA’s acceptance of Summit’s Biologics License Application for ivonescimab plus chemotherapy in EGFR mutated non small cell lung cancer, with a PDUFA date of November 14, 2026. That filing, backed by HARMONi progression free survival data, sits at the center of Summit’s story, and the new gastrointestinal cancer result now feeds into how investors may reassess the breadth and consistency of ivonescimab’s late stage profile.

    Yet investors should also be aware that if future overall survival data in key trials fall short of what regulators have flagged as necessary, then...

    Read the full narrative on Summit Therapeutics (it's free!)

    Summit Therapeutics’ narrative projects $897.3 million in revenue and $169.7 million in earnings by 2029. This implies an earnings increase of about $1.37 billion from -$1.2 billion today.

    Uncover how Summit Therapeutics' forecasts yield a $28.36 fair value, a 99% upside to its current price.

    Exploring Other Perspectives

    SMMT 1-Year Stock Price Chart
    SMMT 1-Year Stock Price Chart

    Before this biliary tract cancer update, the most optimistic analysts were assuming ivonescimab might reach about US$2.5 billion in revenue and roughly US$273 million in earnings by 2029, which is far more upbeat than the consensus view and could shift again as survival data and regulatory decisions evolve.

    Explore 4 other fair value estimates on Summit Therapeutics - why the stock might be worth 22% less than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Curious About Other Options?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.